Bevacizumab for the treatment of high-grade glioma: an update after Phase III trials

Phase II study of biweekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma multiforme.

(2017) M. A. Badruddoja et al.   JOURNAL OF CLINICAL ONCOLOGY

Response Assessment Criteria for Glioblastoma: Practical Adaptation and Implementation in Clinical Trials of Antiangiogenic Therapy

(2013) Olivier L. Chinot et al.   Current Neurology and Neuroscience Reports

Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma

(2013) Tracy T. Batchelor et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab for radiation necrosis following treatment of high grade glioma: a systematic review of the literature

(2013) Daniel Lubelski et al.   JOURNAL OF NEURO-ONCOLOGY

Enhancement of radiation response with bevacizumab

(2012) Tien Hoang et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype

(2012) Y. Piao et al.   NEURO-ONCOLOGY

Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma

(2012) Antonio Omuro et al.   NEURO-ONCOLOGY

Management of treatment-associated toxicites of anti-angiogenic therapy in patients with brain tumors

(2012) T. S. Armstrong et al.   NEURO-ONCOLOGY

Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials

(2011) Silvia Hofer et al.   ACTA ONCOLOGICA

Intracranial hemorrhage in patients with cancer treated with bevacizumab: the Memorial Sloan-Kettering experience

(2011) M. Khasraw et al.   ANNALS OF ONCOLOGY

Angiogenesis and invasion in glioma

(2011) Manabu Onishi et al.   Brain Tumor Pathology

Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy

(2011) David A. Reardon et al.   CANCER

The Addition of Bevacizumab to Standard Radiation Therapy and Temozolomide Followed by Bevacizumab, Temozolomide, and Irinotecan for Newly Diagnosed Glioblastoma

(2011) J. J. Vredenburgh et al.   CLINICAL CANCER RESEARCH

Role of tyrosine kinase inhibitors in the management of high-grade gliomas

(2011) Manmeet S Ahluwalia et al.   Expert Review of Anticancer Therapy

Phase II Study of Aflibercept in Recurrent Malignant Glioma: A North American Brain Tumor Consortium Study

(2011) John F. de Groot et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma

(2011) David A. Reardon et al.   JOURNAL OF NEURO-ONCOLOGY

Safety of concurrent bevacizumab therapy and anticoagulation in glioma patients

(2011) Andrew D. Norden et al.   JOURNAL OF NEURO-ONCOLOGY

Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice

(2011) J. F. de Groot et al.   NEURO-ONCOLOGY

A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas

(2010) Jeffrey J. Raizer et al.   CANCER

Randomized Double-Blind Placebo-Controlled Trial of Bevacizumab Therapy for Radiation Necrosis of the Central Nervous System

(2010) Victor A. Levin et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Addition of Bevacizumab to Standard Radiation Therapy and Daily Temozolomide Is Associated With Minimal Toxicity in Newly Diagnosed Glioblastoma Multiforme

(2010) James J. Vredenburgh et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

(2010) Patrick Y. Wen et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of Bevacizumab Plus Temozolomide During and After Radiation Therapy for Patients With Newly Diagnosed Glioblastoma Multiforme

(2010) Albert Lai et al.   JOURNAL OF CLINICAL ONCOLOGY

Glioblastoma stem-like cells give rise to tumour endothelium

(2010) Rong Wang et al.   NATURE

Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab

(2010) M. Prados et al.   NEURO-ONCOLOGY

Advances in the Treatment of Malignant Gliomas

(2010) Mustafa Khasraw et al.   Current Oncology Reports

Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study

(2009) D A Reardon et al.   BRITISH JOURNAL OF CANCER

Bevacizumab for recurrent alkylator-refractory anaplastic oligodendroglioma

(2009) Marc C. Chamberlain et al.   CANCER

Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis

(2009) Marta Pàez-Ribes et al.   CANCER CELL

Mediators of Glioblastoma Resistance and Invasion during Antivascular Endothelial Growth Factor Therapy

(2009) A. K. Lucio-Eterovic et al.   CLINICAL CANCER RESEARCH

Pseudoprogression and pseudoresponse in the treatment of gliomas

(2009) Dieta Brandsma et al.   CURRENT OPINION IN NEUROLOGY

Safety and Efficacy of Bevacizumab With Hypofractionated Stereotactic Irradiation for Recurrent Malignant Gliomas

(2009) Philip H. Gutin et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

End Point Assessment in Gliomas: Novel Treatments Limit Usefulness of Classical Macdonald's Criteria

(2009) Martin J. van den Bent et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma

(2009) Henry S. Friedman et al.   JOURNAL OF CLINICAL ONCOLOGY

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

(2009) Roger Stupp et al.   LANCET ONCOLOGY

Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab

(2009) Eudocia C. Quant et al.   NEURO-ONCOLOGY

Bevacizumab and irinotecan for recurrent oligodendroglial tumors

(2009) S. Taillibert et al.   NEUROLOGY

Bevacizumab and chemotherapy for recurrent glioblastoma: A single-institution experience

(2009) P. L. Nghiemphu et al.   NEUROLOGY

Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma

(2009) F. M. Iwamoto et al.   NEUROLOGY

Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours

(2008) Hans Skovgaard Poulsen et al.   ACTA ONCOLOGICA

Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors

(2008) Felix Bokstein et al.   CANCER

Incidence of early pseudo‐progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide

(2008) Walter Taal et al.   CANCER

Clinical pharmacokinetics of bevacizumab in patients with solid tumors

(2008) Jian-Feng Lu et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Bevacizumab Plus Irinotecan in Recurrent WHO Grade 3 Malignant Gliomas

(2008) A. Desjardins et al.   CLINICAL CANCER RESEARCH

Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma

(2008) Teri N. Kreisl et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan

(2008) R. M. Zuniga et al.   JOURNAL OF NEURO-ONCOLOGY

Salvage chemotherapy with bevacizumab for recurrent alkylator-refractory anaplastic astrocytoma

(2008) Marc C. Chamberlain et al.   JOURNAL OF NEURO-ONCOLOGY

Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival

(2008) Ashwatha Narayana et al.   JOURNAL OF NEUROSURGERY

Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence

(2008) A. D. Norden et al.   NEUROLOGY

Malignant Gliomas in Adults

(2008) Patrick Y. Wen et al.   NEW ENGLAND JOURNAL OF MEDICINE